Activating mutations in the estrogen receptor 1 (ESR1) gene confer resistance to aromatase inhibitors (AI), and may be targeted by selective estrogen receptor downregulators. We designed a multiplex droplet digital PCR (ddPCR), which combines a drop-off assay, targeting the clustered hotspot mutations found in exon 8, with an unconventional assay interrogating the E380Q mutation in exon 5. We assessed its sensitivity in vitro using synthetic oligonucleotides, harboring E380Q, L536R, Y537C, Y537N, Y537S, or D538G mutations. Further validation was performed on plasma samples from a prospective study and compared with next generation sequencing (NGS) data. The multiplex ESR1-ddPCR showed a high sensitivity with a limit of detection ranging from 0.07 to 0.19% in mutant allele frequency. The screening of plasma samples from patients with AI-resistant metastatic breast cancer identified ESR1 mutations in 29% of them, all mutations being confirmed by NGS. In addition, this test identifies patients harboring polyclonal alterations. Furthermore, the monitoring of circulating tumor DNA using this technique during treatment follow-up predicts the clinical benefit of palbociclib-fulvestrant. The multiplex ESR1-ddPCR detects, in a single reaction, the most frequent ESR1 activating mutations with good sensitivity. This method allows real-time liquid biopsy for ESR1 mutation monitoring in large cohorts of patients.
Introduction
In 2013, several studies reported activating point mutations in the estrogen receptor (ER) gene, ESR1 [1] [2] [3] [4] . These oncogenic mutations activate the ER in a ligandindependent manner and were proposed to be a potential mechanism of resistance to hormone depletion, by aromatase inhibitors (AI), for example. In ER+ HER2-negative metastatic breast cancer (ER+ HER2− MBC) patients, ESR1 mutations are rarely detected in primary tumors or at first metastatic relapse [5, 6] . However, their overall incidence increases alongside the exposure to AI [2, 3, 6, 7] , suggesting that ESR1 mutations are a positively selected resistance mechanism to this treatment. Overall, 30-40% of ER+ HER2− MBC patients who are resistant to AI, carry ESR1 mutations, some even harboring polyclonal ESR1 alterations [8, 9] . These mutations occur in the ligandbinding domain, typically in two hotspot locations: codon 380 (exon 5) and codons 536, 537, and 538 (exon 8) [10] [11] [12] . Importantly, selective ER downregulators retain a significant activity on mutated ER ( Supplementary Table 1 ) [11] . This indicates that mutations in ESR1 could be a predictive biomarker in the management of ER+ MBC [12, 13] . Accurate and sensitive detection tools are therefore needed to initiate clinical trials that investigate the clinical utility of ESR1 mutation monitoring.
Our group, and others, have shown that drop-off droplet digital PCR (ddPCR) is an efficient tool to screen for clustered mutations that can be covered by a single TaqMan probe [14, 15] . The drop-off assay relies on the concept that a single mismatch is sufficient to destabilize the complex 'probe/target' sequence. Hence, any mutation in the region covered by the 'drop-off' probe leads to a loss of signal when compared to wild-type (WT) samples. All previous studies reported high sensitivity and reproducibility for hotspot mutations in the EGFR, KRAS, and BRAF genes [14, 16, 17] .
Here, we present the validation of a novel ddPCR assay, which combines a drop-off ddPCR, targeting the clustered hotspot mutations found in ESR1 exon 8, with an unconventional ddPCR interrogating specifically the E380Q mutation, located in exon 5. This multiplex test detects, in a single reaction, up to 95% of the described activating ESR1 mutations [2, 3, 10, 11, 13, 18] , and is compatible with body fluid samples.
Results

Screening of multiple ESR1 hotspot mutations by ddPCR
Overall, 80% of all ESR1 mutations found in ER+ HER2− MBC patients resistant to AI, corresponding to 95% of functionally characterized ESR1 activating mutations, alter codon 380 in exon 5 and/or the codons 536, 537, and 538 in exon 8 ( Supplementary Table 1 ). We developed a new multiplex ESR1-ddPCR assay targeting these two regions in a single reaction. A first pair of TaqMan probes targets specifically the E380Q mutation in exon 5, using a probe complementary to the E380Q mutant allele (E380Q probe, labeled with FAM fluorophore) and a reference probe spanning an adjacent invariable region (REFex5 probe, labeled with VIC fluorophore) ( Fig. 1a , left panel and Supplementary Methods). In this unconventional E380Q assay, droplets containing WT alleles are VIC-positive only, whereas droplets containing E380Q mutant alleles are double positive (VIC + /FAM + ) ( Fig. 1a , right panel). The second pair of probes targets the clustered mutations in exon 8 using a probe complementary to the WT sequence of the altered region (Hotspot probe, VIC-labeled), which detects all the mutations occurring at codons 536, 537, and 538, together with a reference probe spanning an invariable region within the same amplicon (REFex8 probe, FAMlabeled) ( Fig. 1b , left panel). Therefore, droplets containing WT alleles are double positive (FAM + /VIC + ) whereas the mismatch induced by the mutations leads to a VIC signal decrease (FAM + /VIC low ), resulting in a shift of the droplet cloud (MUT Ex8) toward a single FAM-positive population ( Fig. 1b, right panel) .
The multiplexed assay, combining primers and probes from the E380Q and the drop-off Ex8 assays, allows to screen for mutations in exons 5 and 8 in a single reaction. In a test using synthetic E380Q or D538G oligonucleotides, we could distinguish each WT and mutant clouds for exons 5 and 8 in multiplex conditions ( Fig. 1c ). We observed an additional cloud of droplets containing both WT Ex5 and WT Ex8 amplicons ( Fig. 1c , Cloud #5), which we also find in WT samples (data not shown), as well as a cloud containing E380Q and WT copies when testing for the E380Q mutation ( Fig. 1c , left panel, Cloud #6), and not observed when testing for the D538G mutation.
Detection of polyclonal alterations
In addition to the D538G mutation, we tested four other synthetic oligonucleotides harboring the Y537C, Y537N, Y537S, or L536R mutations found in exon 8. We observed that the position of the MUT Ex8 cloud was dependent on the mutation tested ( Supplementary Fig. 1A ). This suggests that each nucleotide change does not equally destabilize the complex 'probe/target sequence'. The largest shifts were observed for the mutations D538G and Y537C. Both clouds of droplets containing these mutant alleles were localized in the same area and were therefore indistinguishable from each other; whereas the clouds for Y537N, Y537S, and L536R displayed smaller shifts and were distinct from the D538G/Y537C cloud. We further tested the combinations of two mutant oligonucleotides in multiplex conditions confirming that multiple mutations in exon 8 (e.g., D538G + Y537N, D538G + Y537S, D538G + L536R, or Y357N + L536R) display a specific pattern ( Supplementary Fig. 1B ). We also clearly detected the combination of one mutation in exon 8 (e.g., D538G) with E380Q. The multiplex ESR1-ddPCR can thus identify patients carrying polyclonal alterations, as previously reported [8, 9] .
In vitro performances
We further estimated the specificity and sensitivity of the multiplex ESR1-ddPCR by analyzing 48 replicates of WT DNA and serial dilutions of mutant synthetic oligonucleotides recapitulating mutant allele frequencies (MAF) from 0.8 to 0.04% (see Supplementary Materials) . The ESR1-ddPCR assay showed high specificity with a maximum of one false-positive event observed per reaction ( Fig. 2a and Supplementary Table 2 ). The limit of blank (LOB) was estimated at 0.004% for exon 5 mutations and 0.008% for exon 8 mutations. The limit of detection (LOD), defined as the lowest MAF with all replicates presenting values above the LOB, was estimated at 0.19% in mutant allele frequency for E380Q ( Fig. 2b and Supplementary Table 1 ) and ranged from 0.07 to 0.13% depending on the exon 8 mutation tested ( Fig. 2c and Supplementary Table 1 ). LOB and LOD values observed were in the same range under simplex conditions or with conventional ddPCR assays ( Fig. 2 ).
Validation in clinical samples
To validate the performance of the multiplex ESR1-ddPCR assay, we tested a series of 43 plasma samples from a prospective cohort of patients with HR+ HER2− MBC progressing under hormone therapy (Supplementary Methods). Cell-free DNA (cfDNA), extracted from plasma, contains tumor-specific alterations. These alterations identify DNA fragments originating from the tumor, to which we refer as circulating tumor DNA (ctDNA) [19] . We successfully detected ESR1 mutations in 11 out of the 42 (26%) informative patient samples (Table 1 ). Four cases (P-05, P-17, P-37, and P-43) harbored an E380Q mutation (36% of the mutant cases, Supplementary Fig. 2A ) and eight cases (P-08, P-18, P-20, P-25, P-28, P-35, P-39, and P-43) carried at least one mutation in exon 8 (73% of the mutant cases, Supplementary Fig. 2B ). Interestingly, based on the shape and the location of the MUT Ex8 clouds, we detected that samples P-18 and P-28 harbored multiple mutations ( Supplementary Fig. 2C ). We also observed that P-43 harbored ESR1 mutations in both exons 5 and 8 ( Supplementary Fig. 2C ). Thirty-two plasma samples, for which we had sufficient cfDNA, were tested with targeted next generation sequencing (NGS) for head-to-head comparison, with no prior knowledge of ddPCR results (Supplementary methods). The samples included ten mutant and 22 WT cases according to the ddPCR analysis. All ESR1 mutations detected by ddPCR were confirmed by NGS, except for two cases (P-17 and P-20) in which the ESR1 MAF measured by ddPCR was <1% ( Table 1 , Supplementary Fig. 3A ). P-25 was not tested with NGS due to the lack of cfDNA. We also confirmed the WT status of the 22 remaining plasma samples. In case P-18, NGS results indicated that the mutations were D538G and L536H, a combination we did not test before. In case P-28, we observed three mutations in exon 8: L536H, Y537N, and Y537S. Interestingly, for case P-35, NGS showed that the mutation in exon 8 was Y537N, which did not result from the usual C > T substitution in position 1609, but from a small deletion/insertion at nucleotides 1608-1609 (c.1608_1609delinsTA). This could not have been detected by standard ddPCR targeting specifically the C > T substitution in position 1609. We further compared the performance of the multiplex ESR1-ddPCR assay to Fig. 2 In vitro performance of the multiplex ESR1-ddPCR compared with simplex and conventional assays. a False-positive events for exons 5 or 8 mutations observed from pure WT DNA tested with the ESR1-ddPCR in multiplex conditions (LOB E380Q = 0.004%; LOB Exon 8 = 0.008%), simplex conditions (LOB E380Q = 0.003%; LOB Exon 8 = 0.01%) and ESR1 conventional assays (LOB E380Q = 0%; LOB D538G = 0.01%; LOB L536R = 0.0004%; LOB Y537C = 0.009%; LOB Y537N = 0.004%; LOB Y537S = 0%). LOD estimation for exon 5 E380Q mutation (b) and for exon 8 mutations D538G, L536R, Y537C, Y537N, or Y537S (c). The limit of blank (LOB) and limit of detection (LOD), which is estimated as the 95% CI of the mean false-positive calls, displayed are the ones determined for the multiplex ESR1-ddPCR assay. See Supplementary Table 1 and Supplementary Methods for more details. conventional ddPCR targeting specifically the E380Q, L536H, and D538G mutations for patients with sufficient DNA left (P-08, P-18, P-28, P-37, P-39, and P-43) and observed a high concordance in allelic frequencies detected ( Supplementary Table 3 ). Overall, the multiplex ESR1-ddPCR is at least as sensitive and accurate as conventional targeted ESR1 ddPCRs and standard NGS in identifying ESR1 mutation carriers.
Monitoring of circulating ESR1 mutant copies to predict response to palbociclib-fulvestrant therapy
We next analyzed the impact of the ESR1 mutant status, detected with the multiplex ESR1-ddPCR, during the treatment follow-up of an extended cohort including 60 patients. Plasma samples were collected before treatment (D0), after 15 days (D15) and 30 days (D30) of treatment and at the time of progression. Among the 59 patients screened with contributive results, ESR1 mutations were detected in 17 (28.8%), which is in line with proportions of patients progressing under AI treatment previously reported [8, 9, 11, 20] . Fifteen of them had an evaluable progression-free survival (PFS) (Fig. 3a) . The ESR1 mutational status detected at baseline (mutant vs. wild type) had no impact on the PFS (Fig. 3b ). This agrees with the PALOMA-3 trial reporting no improved PFS for ESR1 mutations carriers treated with fulvestrant [11, 20] . We further analyzed the ESR1 mutant copy levels depending on the 3-month disease progression status (progressive disease (PD) vs. non-PD). At baseline, we observed a median number of ctDNA copies of 54/ml of plasma (mean = 188.5, range ) with no apparent association with PD ( Fig. 3c ). After 15 days of treatment, we uncovered a dramatic decrease (median = 0, mean = 14.3, range [0-74]) with 58% of patients (7/12) reaching undetectable ESR1 mutant levels ( Fig. 3c and Supplementary Table 4 ). Remarkably, all patients displayed a decreased ctDNA copy number at D15, compared with D0. At D30, the majority of patients with early disease progression had increased ctDNA levels whereas the majority of patients with longer PFS displayed decreased or stable ctDNA levels (Fig. 3c ). Overall, a lower proportion of patients displayed undetectable ctDNA levels (53% = 8/ 15), the majority of which (87.5% = 7/8) had no early disease progression (Fig. 3d) . Indeed, patients with early disease progression had significantly more ctDNA detected at D30 than patients with longer PFS (p < 0.0001; Fig.  3d ). This ctDNA positivity at D30 correlates with PFS (p = 0.0063; Fig. 3e, f) . Here, we show that the detection of ctDNA after 30 days of palbociclib-fulvestrant is a promising dynamic biomarker associated with PFS.
Discussion
We successfully developed a single ddPCR assay detecting 95% of functionally characterized activating ESR1 mutations, which is compatible with liquid biopsies. Multiplexing a drop-off and an unconventional ddPCRs, we can detect E380Q mutations and all mutations occurring at codons 536-540, in a single reaction. Several teams have previously developed ddPCRs targeting the most frequent ESR1 mutations found in exon 8: D538G, Y537S, Y537N, and Y537C [5, [21] [22] [23] [24] . These assays contain specific TaqMan probes complementary to each mutant or WT allele, which are tested in separate reactions. Multiplex assays were further developed to reduce the number of reactions [8, 12] , detecting maximum 4 ESR1 mutations in a single reaction followed by singleplex confirmation [25] . To our knowledge, we are the first to have developed mutations in a single reaction faster and at a lower cost than NGS or any other currently available technology. The analytical sensitivity of the multiplex ESR1-ddPCR is particularly useful to monitor ctDNA during treatment follow-up. We demonstrated that ESR1 mutations are good markers for ctDNA dynamics exploration and prediction of treatment response. Indeed, we observed that detection of ctDNA after 30 days of palbociclib-fulvestrant, using the ESR1-ddPCR, correlates with the treatment response and has an impact on PFS.
A phase III trial (PADA-1, NCT03079011) is currently testing the clinical utility of real-time ESR1 mutation detection by our assay in ER+ HER2− MBC treated with AI and palbociclib. A preliminary analysis showed that ESR1 mutation detection rate was 3.2% at metastatic relapse (prior to treatment initiation) [26] . Interestingly, a higher percentage (6.4%) was observed among patients exposed to AI in the adjuvant setting. In these patients, ESR1 mutation might, therefore, be detectable before the onset of a clinically detectable metastatic relapse.
Interestingly, we observed that exons 5 and 8 mutations can be easily distinguished. In addition, any nucleotide change covered by the drop-off Ex8 assay can be identified, as confirmed by the detection of the previously unreported mutation Y537N (delinsTA). We observed that, among exon 8 mutations, the shift in clouds depends on the mutation, indicating if the mutation is more likely to be a D538G or Y537C allele versus mutations in codon 536 or other changes in codon 537. However, the fact that this assay does not recover the exact nucleotide change in exon 8 constitutes its most prominent limitation. From a clinical perspective, all mutations in codons 536-538 have been equally associated with resistance to AI therapy. Nonetheless, preclinical data suggest that the Y537S mutation, which accounts for about 10% of all ESR1 mutations, might be less sensitive to fulvestrant than other mutations [11] . If this observation is confirmed to be clinically relevant, the multiplex ESR1-ddPCR could be used as a first screening tool, since the shift associated to Y537S is distinguishable from the most frequent mutation: D538G. A second theoretical limitation is that synonymous mutations may also be detected by this assay. However, ESR1 synonymous mutations, as well as polymorphisms in codons 536-540, are extremely rare.
In conclusion, the multiplex ESR1-ddPCR detects the most frequent ESR1 mutations, in a single reaction, allowing for liquid biopsy real-time monitoring in large cohorts of patients.
